75760-11-1Relevant articles and documents
ALPHA-5 BETA-1 INHIBITORS
-
Paragraph 0323; 0325-0328, (2021/06/11)
The disclosure provides, inter alia, alpha-5 beta-1 inhibitors, pharmaceutical compositions comprising alpha-5 beta-1 inhibitors, methods for treating diseases using alpha-5 beta-1 inhibitors, and processes for making alpha-5 beta-1 inhibitors.
Functional Disruption of the Cancer-Relevant Interaction between Survivin and Histone H3 with a Guanidiniocarbonyl Pyrrole Ligand
Aschmann, Dennis,Bayer, Peter,Beuck, Christine,Ehlers, Martin,Giese, Michael,Killa, Matthias,Knauer, Shirley K.,Meiners, Annika,Mertel, Marcel,Schmuck, Carsten,Vallet, Cecilia
supporting information, p. 5567 - 5571 (2020/02/04)
The protein Survivin is highly upregulated in most cancers and considered to be a key player in carcinogenesis. We explored a supramolecular approach to address Survivin as a drug target by inhibiting the protein–protein interaction of Survivin and its fu
Highly enantioselective synthesis of orthogonally protected (2S)-2,3-diaminopropanoates through catalytic phase-transfer aza-Henry reaction
Kumaraswamy, Gullapalli,Pitchaiah, Arigala
, p. 1543 - 1550 (2011/10/08)
The syntheses of enantiomer-enriched orthogonally protected different (2S)-2,3-diaminopropanoates and unnatural furyl-substituted (tert-butoxy) carbonyl (Boc) as well as (benzyloxy)carbonyl (Cbz) protected amino acid esters are accomplished by means of an